Urologic Oncology: Seminars and Original Investigations
Volume 28, Issue 4 , Pages 441-448 , July 2010

Considerations on implementing diagnostic markers into clinical decision making in bladder cancer

  • Yair Lotan, M.D.

      Affiliations

    • Department of Urology, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    • Corresponding Author InformationCorresponding author. Tel.: 214-648-0389; fax: 214-648-8786
    • ,
  • Shahrokh F. Shariat, M.D., Ph.D.

      Affiliations

    • Division of Urology, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA
    • ,
  • Bernd J. Schmitz-Dräger, M.D., Ph.D.

      Affiliations

    • Urologie, Euromed Clinic, Fürth, Germany
    • ,
  • Marta Sanchez-Carbayo, Ph.D.

      Affiliations

    • Centro Nacional de Investigaciones Oncológicas, Madrid, Spain
    • ,
  • Feliksas Jankevicius, M.D.

      Affiliations

    • Institute of Oncology, Vilnius University, Vilnius, Lithuania
    • ,
  • Marco Racioppi, M.D.

      Affiliations

    • Clinica Urologica, Università Cattolica del S. Cuore, Rome, Italy
    • ,
  • Sarah J.P. Minner, M.D.

      Affiliations

    • Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
    • ,
  • Brigitte Stöhr, MDFi

      Affiliations

    • Department of Urology, University of Innsbruck, Innsbruck, Austria
    • ,
  • Pier Francesco Bassi, M.D.

      Affiliations

    • Clinica Urologica, Università Cattolica del S. Cuore, Rome, Italy
    • ,
  • H. Barton Grossman, M.D.

      Affiliations

    • Department of Urology, Division of Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA

References 

  1. Herman MP, Svatek RS, Lotan Y, et al. Urine-based biomarkers for the early detection and surveillance of non-muscle-invasive bladder cancer. Minerva Urol Nefrol. 2008;60:217–235
  2. Babjuk MA, Oosterlinck W, Sylvester R, et al. Guidelines on TaT1 (non-muscle-invasive) bladder cancer. In:  Aus G,  Hanus T,  Irani J, et al. editor. Arnhem, The Netherlands: European Association of Urology: Guidelines. Arnhem, The Netherlands: EAU; 2008;p. 1–22
  3. Bensalah K, Montorsi F, Shariat SF. Challenges of cancer biomarker profiling. Eur Urol. 2007;52:1601–1609
  4. Lotan Y, Shariat SF NMP22 Study Group. Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection. BJU Int. 2008;101:1362–1367
  5. Shariat SF, Karakiewicz PI, Suardi N, et al. Comparison of nomograms with other methods for predicting outcomes in prostate cancer: A critical analysis of the literature. Clin Cancer Res. 2008;14:4400–4407
  6. Shariat SF, Margulis V, Lotan Y, et al. Nomograms for bladder cancer. Eur Urol. 2008;54:41–53
  7. Vickers AJ, Jang K, Sargent D, et al. Systematic review of statistical methods used in molecular marker studies in cancer. Cancer. 2008;112:1862–1868
  8. Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: Results of a comprehensive literature review and meta-analyses. Urology. 2003;61:109–118
  9. Lokeshwar VB, Habuchi T, Grossman HB, et al. Bladder tumor markers beyond cytology: Bladder tumor markers consensus panel. Urology. 2005;66(Suppl 6A):35–63
  10. Shariat SF, Canto EI, Kattan MW, et al. Beyond prostate-specific antigen: New serologic biomarkers for improved diagnosis and management of prostate cancer. Rev Urol. 2004;6:58–72
  11. Goebell PJ, Groshen S, Schmitz-Dräger BJ. Guidelines for development of diagnostic markers in bladder cancer. W J Urol. 2008;26:5–11
  12. McShane LM, Altman DG, Sauerbrei W, et al. Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics Reporting recommendations for tumor Marker prognostic studies (REMARK). Nat Clin Pract Urol. 2005;2:416–422
  13. Shariat SF, Zippe C, Lüdecke G, et al. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1, or CIS transitional cell carcinoma of the bladder. J Urol. 2005;173:1518–1525
  14. Lotan Y, Capitanio U, Shariat SF, et al. Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection. BJU Int. 2009;103:1368–1374
  15. Steiner H, Bergmeister M, Verdorfer I, et al. Early results of bladder-cancer screening in a high-risk population of heavy smokers. BJU Int. 2008;102:291–296
  16. Madeb R, Messing EM. Long-term outcome of home dipstick testing for hematuria. World J Urol. 2008;26:19–24
  17. Lotan Y, Elias K, Svatek RS, et al. Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker. J Urol. 2009;182:52–57
  18. Schmitz-Dräger BJ, Tirsar L-A, Schmitz-Dräger C, et al. Immunocytology in the assessment of patients with gross hematuria. Br J Urol. 2008;101:455–458
  19. Grossfeld GD, Litwin MS, Wolf JS, et al. Evaluation of asymptomatic microscopic hematuria in adults: The American Urological Association best practice policy (Part I: Definition, detection, prevalence, and etiology). Urology. 2001;57:599–603
  20. Mariani AJ, Mariani MC, Macchioni C, et al. The significance of adult hematuria: 1,000 hematuria evaluations including a risk-benefit and cost-effectiveness analysis. J Urol. 1989;141:350–355
  21. Cohen RA, Brown RS. Clinical practice (Microscopic hematuria). N Engl J Med. 2003;348:2330–2338
  22. Schmitz-Dräger BJ, Beiche B, Tirsar L-A, et al. Immunocytology in the assessment of patients with asymptomatic microhematuria. Eur Urol. 2007;51:1582–1588
  23. Schmitz-Dräger BJ, Tirsar L-A, Schmitz-Dräger C, et al. Immunocytology in the assessment of patients with asymptomatic hematuria. W J Urol. 2008;26:31–37
  24. Yoder BJ, Skacel M, Hedgepeth R, et al. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: A prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol. 2007;127:295–301
  25. Grossman HB, Soloway M, Messing E, et al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA. 2006;295:299–305
  26. Hajdinjak T. UroVysion FISH test for detecting urothelial cancers: Meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. Urol Oncol. 2008;26:646–651
  27. Konety B, Lotan Y. Urothelial bladder cancer: Biomarkers for detection and screening. BJU Int. 2008;102:1234–1241
  28. Soloway MS. Expectant treatment of small, recurrent, low-grade, noninvasive tumors of the urinary bladder. Urol Oncol. 2006;24:58–61
  29. Grossman HB, Messing E, Soloway M, et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA. 2005;293:810–816
  30. Messing E, Madeb MR, Young T, et al. Long-term outcome of hematuria home screening for bladder cancer in men. Cancer. 2006;107:2173–2179
  31. Lachaine J, Valiquette L, Crott R. Economic evaluation of NMP22 in the management of bladder cancer. Can J Urol. 2000;7:974–980
  32. Lodde M, Mian C, Comploj E, et al. uCyt+ test: Alternative to cystoscopy for less-invasive follow-up of patients with low risk of urothelial carcinoma. Urology. 2006;67:950–954
  33. Lotan Y, Bensalah K, Ruddell T, et al. Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. J Urol. 2008;179:2164–2169
  34. Skacel M, Fahmy M, Brainard JA, et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol. 2003;169:2101–2105
  35. Yoder BJ, Skacel M, Hedgepeth R, et al. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: A prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol. 2007;127:295–301
  36. Schröder FH, Hugosson J, Roobol MJ, et al. ERSPC Investigators Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320–1328
  37. Andriole GL, Crawford ED, Grubb RL, et al. PLCO Project Team Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310–1319
  38. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2,596 patients from seven EORTC trials. Eur Urol. 2006;49:466–477
  39. Gofrit ON, Zorn KC, Silvestre J, et al. The predictive value of multi-targeted fluorescent in-situ hybridization in patients with history of bladder cancer. Urol Oncol. 2008;26:246–249
  40. Schneeweiss S, Kriegmair M, Stepp H. Is everything all right if nothing seems wrong? (A simple method of assessing the diagnostic value of endoscopic procedures when a gold standard is absent). J Urol. 1999;161:1116–1119
  41. Hungerhuber E, Stepp H, Kriegmair M, et al. Seven years' experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder. Urology. 2007;69:260–264
  42. Svatek RS, Lee D, Lotan Y. Correlation of office-based cystoscopy and cytology with histologic diagnosis: How good is the reference standard?. Urology. 2005;66:65–68
  43. Paez A, Coba JM, Murillo N, et al. Reliability of the routine cytological diagnosis in bladder cancer. Eur Urol. 1999;35:228–232
  44. Raitanen MP, Aine R, Rintala E, et al. Differences between local and review urinary cytology in diagnosis of bladder cancer (An interobserver multicenter analysis). Eur Urol. 2002;41:284–289
  45. Nabi G, Greene DR, O'Donnell M. How important is urinary cytology in the diagnosis of urological malignancies?. Eur Urol. 2003;43:632–636
  46. Nabi G, Greene D, O'Donnell MO. Suspicious urinary cytology with negative evaluation for malignancy in the diagnostic investigation of hematuria: How to follow up?. J Clin Pathol. 2004;57:365–368
  47. Raitanen MP, Aine R, Kylmala T, et al. The dilemma of suspicious urine cytology in patients being followed for bladder cancer. Ann Chir Gynaecol. 2001;90:256–259
  48. Nieder AM, Lotan Y, Nuss GR, et al. Are patients with hematuria appropriately referred to Urology? (A multi-institutional questionnaire based survey). Urol Oncol. 2008, Dec 19;[Epub ahead of print]
  49. Johnson EK, Daignault S, Zhang Y, et al. Patterns of hematuria referral to urologists: Does a gender disparity exist?. Urology. 2008;72:498–502
  50. Lotan Y, Svatek RS, Sagalowsky AI. Should we screen for bladder cancer in a high-risk population? (A cost per life-year saved analysis). Cancer. 2006;107:982–990
  51. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 9 Regs Public-Use, Nov 2004 Sub (1973–2002), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch released April 2005, based on the November 2004 submission.
  52. Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: Theoretical considerations and practical challenges. J Clin Oncol. 2009;27:4027–4034
  53. Mandrekar SJ, Grothey A, Goetz MP, et al. Clinical trial designs for prospective validation of biomarkers. Am J Pharmacogenomics. 2005;5:317–325
  54. Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: One size does not fit all. J Biopharm Stat. 2009;19:530–542

☆ Results from a consensus meeting of the International Bladder Cancer Network (IBCN), Barcelona, Spain, October 16–17, 2008.

PII: S1078-1439(09)00357-3

doi: 10.1016/j.urolonc.2009.11.004

Urologic Oncology: Seminars and Original Investigations
Volume 28, Issue 4 , Pages 441-448 , July 2010

Article Tools

* Image Usage & Resolution